Marker Therapeutics Files Q2 2024 10-Q

TL;DR

Marker Therapeutics Q2 10-Q filed. Equity details updated.

AI Summary

Marker Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company, formerly known as TAPIMMUNE INC. and GENEMAX CORP, is involved in pharmaceutical preparations. Financial details such as Additional Paid-In Capital and Common Stock are reported for the periods ending June 30, 2024, and March 31, 2024, with comparative data from 2023. The filing also includes information on Retained Earnings as of June 30, 2024, and March 31, 2024.

Why It Matters

This filing provides investors with an update on Marker Therapeutics' financial health and equity structure for the second quarter of 2024, crucial for understanding the company's ongoing operations and potential.

Risk Assessment

Risk Level: medium — As a pharmaceutical company, Marker Therapeutics faces inherent risks related to drug development, regulatory approvals, and market competition, which are not detailed in this specific filing but are typical for the industry.

Key Numbers

• 2024-06-30 — Reporting Period End Date (Indicates the end of the financial quarter being reported.)
• 2024-08-14 — Filing Date (The date the 10-Q was officially submitted to the SEC.)
• 2023-06-30 — Comparative Period End Date (Provides a point of comparison for financial performance from the previous year.)

Key Players & Entities

• Marker Therapeutics, Inc. (company) — Filer of the 10-Q
• TAPIMMUNE INC. (company) — Former company name
• GENEMAX CORP (company) — Former company name
• 20240630 (date) — End of reporting period
• 20240814 (date) — Filing date

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share MRKR The Nasdaq Stock Mar

Filing Documents

• mrkr-20240630x10q.htm (10-Q) — 1236KB
• mrkr-20240630xex31d1.htm (EX-31.1) — 13KB
• mrkr-20240630xex31d2.htm (EX-31.2) — 13KB
• mrkr-20240630xex32d1.htm (EX-32.1) — 7KB
• mrkr-20240630xex32d2.htm (EX-32.2) — 6KB
• mrkr-20240630x10q001.jpg (GRAPHIC) — 12KB
• mrkr-20240630x10q002.jpg (GRAPHIC) — 46KB
• mrkr-20240630x10q003.jpg (GRAPHIC) — 30KB
• 0001410578-24-001454.txt ( ) — 5430KB
• mrkr-20240630.xsd (EX-101.SCH) — 39KB
• mrkr-20240630_cal.xml (EX-101.CAL) — 31KB
• mrkr-20240630_def.xml (EX-101.DEF) — 168KB
• mrkr-20240630_lab.xml (EX-101.LAB) — 306KB
• mrkr-20240630_pre.xml (EX-101.PRE) — 259KB
• mrkr-20240630x10q_htm.xml (XML) — 753KB

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION 1 Item 1.

Financial Statements (Unaudited)

Financial Statements (Unaudited) 1 Condensed Consolidated Balance Sheets As of June 30, 2024 and December 31, 2023 1 Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2024 and 2023 2 Condensed Consolidated Statements of Stockholders' Equity for the three and six months ended June 30, 2024 and 2023 3 Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2024 and 2023 4 Notes to Condensed Consolidated Financial Statements 5 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations. 16 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk. 27 Item 4.

Controls and Procedures

Controls and Procedures. 27

– OTHER INFORMATION

PART II – OTHER INFORMATION 27 Item 1. Legal Proceedings. 27 Item 1A. Risk Factors. 27 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds. 28 Item 3. Defaults Upon Senior Securities. 28 Item 4. Mine Safety Disclosure. 28 Item 5. Other Information. 28 Item 6. Exhibits. 29

Signatures

Signatures 31 Table of Contents

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Financial Statement s

Item 1. Financial Statement s MARKER THERAPEUTICS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) June 30, December 31, 2024 2023 ASSETS Current assets: Cash and cash equivalents $ 7,800,464 $ 15,111,450 Prepaid expenses and deposits 1,384,394 988,126 Other receivables 2,490,147 1,027,815 Total current assets 11,675,005 17,127,391 Total assets $ 11,675,005 $ 17,127,391 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable and accrued liabilities $ 1,679,672 $ 1,745,193 Related party payable 292,569 1,329,655 Total current liabilities 1,972,241 3,074,848 Total liabilities 1,972,241 3,074,848 Stockholders' equity: Preferred stock, $ 0.001 par value, 5 million shares authorized, 0 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively — — Common stock, $ 0.001 par value, 30 million shares authorized, 8.9 million shares issued and outstanding as of June 30, 2024 and December 31, 2023 (see Note 9) 8,922 8,891 Additional paid-in capital 450,565,204 450,329,515 Accumulated deficit ( 440,871,362 ) ( 436,285,863 ) Total stockholders' equity 9,702,764 14,052,543 Total liabilities and stockholders' equity $ 11,675,005 $ 17,127,391 See accompanying notes to these unaudited condensed consolidated financial statements. 1 Table of Contents MARKER THERAPEUTICS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) For the Three Months Ended For the Six Months Ended June 30, June 30, 2024 2023 2024 2023 Revenues: Grant income $ 1,169,236 $ 762,658 $ 2,413,297 $ 1,996,995 Total revenues 1,169,236 762,658 2,413,297 1,996,995 Operating expenses: Research and development 2,335,430 2,377,993 4,910,446 5,754,492 General and administrative 1,141,871 2,518,725 2,359,934 4,686,044 Total operating expenses 3,477,301 4,896,718 7,270,380 10,440,53

View Full Filing

View this 10-Q filing on SEC EDGAR